Business of Cannabis Maps 2026 Cannabis Stocks and How They Trade

The listing map is still split by federal law

Plant-touching U.S. operators still can't list on the major U.S. exchanges, so most of their trading happens elsewhere. That one fact organizes the entire sector.

Multi-state operators (MSOs) typically list on the Canadian Securities Exchange and trade in the U.S. over the counter. Canadian licensed producers and plant-adjacent businesses, such as ancillary suppliers and REITs, can access exchanges that U.S. plant-touching companies can't.

Business of Cannabis framed its 2026 guide around three questions: what is listed, what is next, and how the market trades. We worked from the guide's published headline and framing. We haven't reproduced its ticker-level data here. We won't characterize figures we haven't verified.

How the market trades: thin liquidity, heavy tax drag

Cannabis equities trade on policy expectations more than on earnings, because tax and access constraints cap what fundamentals can deliver. The cleanest read on this sector is that the price is a bet on federal law.

Start with Section 280E of the Internal Revenue Code. It bars businesses trafficking in Schedule I or II substances from deducting ordinary business expenses. Operators with healthy gross margins can still post punishing after-tax results.

Then add the plumbing. Over-the-counter listings carry thinner volume and wider spreads than a Nasdaq or NYSE name, and many institutional mandates can't touch them at all. Liquidity is thin. A single headline can move a ticker more than a quarterly report.

That's why the same company can look cheap on EBITDA and expensive on cash taxes paid. Investors who ignore that gap are reading the wrong line of the income statement.

What's next depends on three federal gates

The next wave of listings hinges on federal scheduling, banking access, and exchange rules, not on company performance. Operators can't control any of them.

• Rescheduling: If the DEA finalizes a move of marijuana to Schedule III, 280E would no longer apply to those businesses, since the statute covers only Schedules I and II.
• Banking access: Legislation such as the SAFER Banking Act would widen access to ordinary financial services and could ease the capital-markets constraints on U.S. operators.
• Exchange standards: Nasdaq and NYSE listing rules would have to change, or federal law would have to change underneath them, before U.S. plant-touching companies could move over.

Rescheduling alone wouldn't legalize anything. It would change the tax math, not the listing eligibility. Those are separate problems, and the market often prices them as one.

Our read: a tax fix without a listing fix lifts cash flow but leaves liquidity where it is, so the first winners would be balance sheets, not share-price multiples.

What operators and investors should watch

Treat every cannabis ticker as two investments: a business and a policy option. Pricing them separately is the only way to judge whether a rally is earned.

Operators should model cash taxes under both 280E and a post-280E scenario. Investors should check where a name trades, how many shares move on a typical day, and whether a headline or a quarter drove the last big swing. Not every listed name is investable at size.

For full background on this story, see the CannIntel topic hub on cannabis stocks and market trading in 2026. State markets such as California, Ohio, and Florida will keep feeding operator revenue regardless of what Washington does, which is why the federal variables carry so much weight in valuation.

The next signal: any DEA final action on scheduling, followed by whether Nasdaq or NYSE say anything about listing eligibility. Until both move, the trading map stays as drawn.